Preclinical models suggest BPC-157 repairs esophageal tissue faster than omeprazole at 14 days, but PPIs have decades of human safety data and FDA approval BPC-157 has neither
Pour y faire face, seules une rnovation et une extension des locaux permettront de garantir qualit, scurit et efficacit
In practical terms, both compounds currently sit in a transitional regulatory status: no longer explicitly restricted, but not yet authorized for routine compounding either
48 CMSs recent reinterpretation of statutory exclusions to allow AOM coverage for obesity treatment projects that 3.3 million Medicare beneficiaries would become eligible, with an estimated 10% initiating treatment, underscoring the potential for considerable access expansion
doi: 10.1056/NEJMoa1809944 67
N Engl J Med 2025;392:2089-2099